This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Animal Pharmacometabolomics
Animal pharmacometabolomics refers to the application of metabolomics in measuring the metabolic characteristics of drug responses and drug variant responses in biological systems. The pharmacological effects of drugs are closely related to the interaction between epigenetic factors, environmental factors, individual animal characteristics, and disease-related factors. BioVenic offers tailored solutions for personalized animal drug metabolomics, which aim to identify metabolic pathways associated with drug effects in research. This service allows comprehensively understand the pharmacological effects, mechanisms, safety, and efficacy of drugs from various perspectives. We provide a user-friendly solution for our scientific customers to utilize high-throughput targeted metabolomics in order to assess the absorption, distribution, and elimination of drugs in animals, while also tracking changes in drug concentration over time. We leverage the potential and advantages of metabolomic approaches to design innovative and personalized veterinary drug therapies by offering quantitative pharmacometabolomic assays.
Fig.1 Schematic Diagram of Applying Pharmacometabolomics in Drug Development. 1
Animal Pharmacometabolomics Services
- Animal Sample Preparation
Our pharmacometabolomics sample preparation service can isolate biomarkers from a variety of animal samples, including urine, blood, feces, milk, and more. We offer tailored sample collection and processing plans based on the specific requirements of your scientific research project. These plans support sampling at various treatment intervals and can be further divided based on the individual animals' drug response.
- Targeted Pharmacometabolomics Detection
BioVenic has developed an advanced and comprehensive animal metabolomics detection platform. This platform allows for the qualitative and quantitative detection and analysis of a wide range of metabolites with complex chemical structures involved in the drug metabolism process. These metabolites exhibit different functional groups and physical and chemical properties. Depending on the customer's specific test sample, we offer standardized methods based on nuclear magnetic resonance (NMR) and mass spectrometry (MS), as well as refined solutions combined with gas or liquid chromatography, capillary electrophoresis, or ultra-performance liquid chromatography (UPLC).
- Data Analysis
In the process of data analysis services, BioVenic combines the use of pharmacokinetics and pharmacometabolomics software modules to complete comprehensive analysis and statistical workflow of detection data. At the same time, we also support customers to identify multiple individual metabolites for a single drug and build a metabolomics database to serve research in the development of personalized treatment options.
- Absolute Quantitation
BioVenic has developed a comprehensive set of quantification and verification processes for biomarkers in typical drug metabolism processes. These processes include isotope labeling and standard comparison methods, as well as quality control measures for standard curves and data. We utilize mass spectrometry and drug concentration determination methods to deliver accurate test results and reports for ongoing scientific research projects. Our aim is to detect drug metabolism levels in animals and monitor biomarkers, ensuring high-quality data.
Flow Chart of Animal Targeted Metabolomics Analysis Service
Applications of Pharmacometabolomics in Veterinary Research
Pharmacometabolomics is a relatively new addition to the field of "omics" research. At present, there are only a few pharmacometabolomics studies on animals, focusing on the development and evaluation of veterinary drugs, pharmacokinetic studies, and the discovery of related biomarkers. Functional metabolites related to drug metabolism offer a range of powerful tools for animal omics research. These tools include predicting the response of diseased animals to treatment, monitoring changes in the physiological state of animals during the use of veterinary drugs and evaluating the ultimate treatment outcome. Software and informatics systems with sophisticated artificial intelligence algorithms enable in-depth analysis of pharmacometabolomics data to explore and establish personalized treatment options, also known as personalized medicine. This approach holds great promise in the field of companion animal healthcare. As an emerging field, animal pharmacometabolomics still faces numerous challenges, such as the sensitivity of analytical techniques, expanding databases, and standardizing study protocols.
Why Choose Us?
Extensive experience in animal metabolomic analysis projects.
Comprehensive technology platform for detection and identification that can satisfy both qualitative and quantitative needs with high sensitivity and precision.
Team of experts in pharmacokinetics and animal metabolomics guides and participates in the design and implementation of the service plan throughout the process.
One-stop animal pharmacometabolomics quantitative detection solution with standardized process.
BioVenic is equipped with a dedicated statistical analysis platform and database construction for animal pharmacometabolomics services. This allows scientific researchers to utilize this emerging high-throughput tool to investigate individual variations in drug response and safety, as well as to identify biomarkers for common animal diseases. These markers will be used to predict and develop personalized drug prescriptions, minimize toxicity, and detect lack of efficacy. Our pharmacometabolomics strategies provide a direct assessment of the metabolic and physiological status of individual animals, which allows for the monitoring of every stage of progression, starting from the exposome, through health and disease, and finally to treatment efficacy. Feel free to contact us and learn more about our services.
References
- Tee, Khim Boon, et al. "Pharmacokinetic–pharmacometabolomic approach in early-phase clinical trials: A way forward for targeted therapy in type 2 diabetes." Pharmaceutics 14.6 (2022): 1268.
- Gonzalez-Covarrubias, Vanessa, Eduardo Martínez-Martínez, and Laura del Bosque-Plata. "The potential of metabolomics in biomedical applications." Metabolites 12.2 (2022): 194.